The goal of this study was to assess the role of SPHK1 in antitumor immunity, reveal a novel molecular mechanism regarding the regulation of PD-L1 via MTA3, and further investigate the clinical significance of the SPHK1-MTA3 axis in immunotherapy in melanoma. This evidence concerns the gene SPHK1 and melanoma.